Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2022 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
Cancer Res Treat. 2023 Oct;55(4):1363-1368. doi: 10.4143/crt.2023.371. Epub 2023 Jun 14.
Cancer Res Treat. 2023.
PMID: 37321275
Free PMC article.
Dual epigenetic agents plus rituximab-gemcitabine-oxaliplatin as salvage treatment in relapsed/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy.
Qu C, Ping N, Kong D, Liu A, Liu H, Xu T, Xia F, Wu D, Jin Z.
Qu C, et al.
Hematol Oncol. 2022 Dec;40(5):914-921. doi: 10.1002/hon.3052. Epub 2022 Aug 12.
Hematol Oncol. 2022.
PMID: 35856472
Item in Clipboard
CAR-T therapy bridging to allogeneic HSCT provides durable molecular remission of Ph+ mixed phenotype acute leukaemia with minimal residual disease.
Kong D, Qu C, Dai H, Li Z, Yin J, Chen S, Kang L, Chen G, Zhu M, Yu L, Wu D, Tang X.
Kong D, et al.
Br J Haematol. 2020 Oct;191(2):e47-e49. doi: 10.1111/bjh.16982. Epub 2020 Jul 22.
Br J Haematol. 2020.
PMID: 32700338
Free article.
Clinical Trial.
No abstract available.
Item in Clipboard
Cite
Cite